Diamond is currently conducting a Phase 2a clinical study evaluating low, sub-perceptual doses of its psilocybin formulation in patients with generalized anxiety disorder (GAD). The study is designed to better understand the relationship between dose, dosing frequency, safety, tolerability, and potential therapeutic benefit.

Under the agreement, Diamond is exploring the integration of its psilocybin formulation with the OnDosis device (Dosage Manager) for use in ongoing and future research and development activities. Subject to regulatory review and approval, the partnership aims to advance the integrated technology to a commercial setting, creating continuity between clinical development and later-stage deployment.

Diamond is investigating psychoactive low-dose psilocybin as a potential treatment approach for mood, psychiatric, and other disorders, with the aim of developing differentiated therapies that may help address unmet needs in mental health care.

Martin Olovsson, CEO of OnDosis said: “This important step highlights the applicability of our Dosage Manager in emerging therapeutic areas such as psychedelic medicine. By enabling individualized dosing whilst supporting controlled administration, we aim to support treatment models suitable for home use while reducing demands on healthcare systems.”